Cargando…

Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity

Multiple natural killer (NK) cell-based anticancer therapies are currently under development. Here, we compare the efficiency of genetically modified NK-92 cells expressing chimeric antigen receptors (CARs) at killing NK cell-resistant B-lymphoid leukemia cells to the antibody-dependent cell-mediate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boissel, Laurent, Betancur-Boissel, Monica, Lu, Weiquan, Krause, Daniela S, Van Etten, Richard A, Wels, Winfried S, Klingemann, Hans
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3881109/ https://www.ncbi.nlm.nih.gov/pubmed/24404423 http://dx.doi.org/10.4161/onci.26527

Ejemplares similares

Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells
por: Klingemann, Hans, et al.
Publicado: (2016)

Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor
por: Gossel, Leonie D. H., et al.
Publicado: (2021)

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
por: Romanski, Annette, et al.
Publicado: (2016)

Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting
por: Eitler, Jiri, et al.
Publicado: (2021)

CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated
por: Kim, Hyori, et al.
Publicado: (2023)

P33. NK-92 cellular immunotherapy as an alternative to donor derived peripheral blood NK cells
por: Klingemann, H
Publicado: (2014)

An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele
por: Jochems, Caroline, et al.
Publicado: (2016)

Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity
por: Zhang, Congcong, et al.
Publicado: (2017)

Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway
por: Althaus, Jonas, et al.
Publicado: (2023)

Optimizing NK-92 serial killers: gamma irradiation, CD95/Fas-ligation, and NK or LAK attack limit cytotoxic efficacy
por: Navarrete-Galvan, Lydia, et al.
Publicado: (2022)

Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123
por: Morgan, Michael A., et al.
Publicado: (2021)

Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML
por: Brauneck, Franziska, et al.
Publicado: (2021)

Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting
por: Sutherland, Ashley R., et al.
Publicado: (2020)

High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia
por: Müller, Stephan, et al.
Publicado: (2020)

Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells
por: Pinz, Kevin G., et al.
Publicado: (2017)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023)

Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody
por: Chen, Ying, et al.
Publicado: (2017)

Detection of Antibody-Dependent Cell-Mediated Cytotoxicity—Supporting Antibodies by NK-92-CD16A Cell Externalization of CD107a: Recognition of Antibody Afucosylation and Assay Optimization
por: Cruz Amaya, Judith, et al.
Publicado: (2023)

EGFR-Targeted Granzyme B Expressed in NK Cells Enhances Natural Cytotoxicity and Mediates Specific Killing of Tumor Cells
por: Oberoi, Pranav, et al.
Publicado: (2013)

A Soluble NK-CAR Mediates the Specific Cytotoxicity of NK Cells toward the Target CD20(+) Lymphoma Cells
por: Liu, Rongjiao, et al.
Publicado: (2022)

CD33 Delineates Two Functionally Distinct NK Cell Populations Divergent in Cytokine Production and Antibody-Mediated Cellular Cytotoxicity
por: Hejazi, Maryam, et al.
Publicado: (2022)

Arming NK cells with enhanced antitumor activity: CARs and beyond
por: Oberoi, Pranav, et al.
Publicado: (2013)

Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies
por: Cappuzzello, Elisa, et al.
Publicado: (2016)

Characterization of BIS20x3, a bi-specific antibody activating and retargeting T-cells to CD20-positive B-cells
por: Withoff, S, et al.
Publicado: (2001)

CD16(+)NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice
por: Williams, Brent A., et al.
Publicado: (2018)

Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy
por: Zhang, Jianguang, et al.
Publicado: (2019)

Adapter Chimeric Antigen Receptor (AdCAR)-Engineered NK-92 Cells for the Multiplex Targeting of Bone Metastases
por: Grote, Stefan, et al.
Publicado: (2021)

Enhanced NK-92 Cytotoxicity by CRISPR Genome Engineering Using Cas9 Ribonucleoproteins
por: Huang, Rih-Sheng, et al.
Publicado: (2020)

A New Mechanism of NK Cell Cytotoxicity Activation: The CD40–CD40 Ligand Interaction
por: Carbone, Ennio, et al.
Publicado: (1997)

Favorable in vitro effects of combined IL-12 and IL-18 treatment on NK cell cytotoxicity and CD25 receptor expression in metastatic melanoma patients
por: Mirjačić Martinović, Katarina, et al.
Publicado: (2015)

T cells, particularly activated CD4(+) cells, maintain anti-CD20-mediated NK cell viability and antibody dependent cellular cytotoxicity
por: Wang, Zhaoming, et al.
Publicado: (2021)

CD86 Is an Activation Receptor for NK Cell Cytotoxicity against Tumor Cells
por: Peng, Yanmeng, et al.
Publicado: (2013)

Anaplasma phagocytophilum-Related Defects in CD8, NKT, and NK Lymphocyte Cytotoxicity
por: Scorpio, Diana G., et al.
Publicado: (2018)

CD8(+) T Lymphocyte and NK Cell Network: Circuitry in the Cytotoxic Domain of Immunity
por: Uzhachenko, Roman V., et al.
Publicado: (2019)

CD56 regulates human NK cell cytotoxicity through Pyk2
por: Gunesch, Justin T, et al.
Publicado: (2020)

ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma
por: Heim, Catrin, et al.
Publicado: (2023)

Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells
por: Roex, Gils, et al.
Publicado: (2022)

“UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells
por: Mitwasi, Nicola, et al.
Publicado: (2020)

Effects of total flavonoids of sea buckthorn (Hippophae rhamnoides L.) on cytotoxicity of NK92-MI cells
por: Hou, Diandong, et al.
Publicado: (2017)

Acute exercise mobilizes CD8(+) cytotoxic T cells and NK cells in lymphoma patients
por: Koivula, Tiia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gbt1n8945kpb3556ihm7fu257h